


IN THE CLAIMS:

Please amend claims 1, 7, and 11 and add new claim 12:

A 2

1. (AMENDED) A compound of the formula I,



wherein

m is 0, 1, 2, 3, or 4;

n is 0, 1, 2, or 3;

A is halogen;

X is sulfur or oxygen;

R^1 is chosen from hydrogen, hydroxy, $(\text{C}_1\text{-C}_{12})$ -alkoxycarbonyl-, $(\text{C}_6\text{-C}_{14})$ -aryl- $(\text{C}_1\text{-C}_4)$ -alkoxycarbonyl-, and $(\text{C}_6\text{-C}_{14})$ -aryloxycarbonyl-, wherein each of the aryl groups is unsubstituted or substituted by at least one identical or different substituent chosen from $(\text{C}_1\text{-C}_{12})$ -alkyl, halogen and $(\text{C}_1\text{-C}_{12})$ -alkoxy;

A 2

R² is chosen from hydrogen, (C₁-C₁₂)-alkyl, (C₆-C₁₄)-aryl, (C₆-C₁₄)-aryl-(C₁-C₄)-alkyl-, R²⁰-(C₁-C₁₂)-alkyl-, R²⁰-(C₆-C₁₄)-aryl-, and R²⁰-(C₆-C₁₄)-aryl-(C₁-C₄)-alkyl-, wherein R²⁰ is chosen from hydroxycarbonyl-, aminocarbonyl-, (C₁-C₁₂)-alkoxycarbonyl-, and (C₆-C₁₄)-aryl-(C₁-C₄)-alkoxycarbonyl-;

R³ is chosen from hydrogen, cyano, hydroxy, and (C₁-C₁₂)-alkyl;

R⁴ is chosen from (C₁-C₁₂)-alkyl, (C₆-C₁₄)-aryl, (C₆-C₁₄)-aryl-(C₁-C₄)-alkyl-, Het, and Het-(C₁-C₄)-alkyl-, wherein the alkyl, aryl and Het groups are unsubstituted or substituted by at least one identical or different substituent R¹⁰;

R⁵ is chosen from hydrogen, (C₁-C₁₂)-alkyl, (C₆-C₁₄)-aryl, (C₆-C₁₄)-aryl-(C₁-C₄)-alkyl-, Het, Het-(C₁-C₄)-alkyl-, (C₆-C₁₄)-aryl-(C₁-C₄)-alkyl-aminocarbonyl-, and Het-(C₁-C₄)-alkyl-aminocarbonyl-, wherein the alkyl, aryl and Het groups are unsubstituted or substituted by at least one identical or different substituent R¹⁰;

or

R⁴ and R⁵ together with the carbon atom to which they are bonded form a saturated or unsaturated 3-membered to 8-membered ring which is a carbocyclic ring or a heterocyclic ring containing 1, 2 or 3 identical or different ring heteroatoms chosen from nitrogen, oxygen and sulfur, and which is optionally condensed to one or two saturated or unsaturated

A 2

carbocyclic ring systems or heterocyclic ring systems containing 5 to 10 ring atoms of which 1, 2 or 3 are identical or different ring heteroatoms chosen from nitrogen, oxygen and sulfur, wherein the resulting $R^4(R^5)C$ group is unsubstituted or substituted by at least one identical or different substituent R^{10} ;

R^6 is chosen from hydrogen, hydroxy, (C_1-C_8) -alkoxy, and (C_6-C_{14}) -aryl- (C_1-C_4) -alkoxy-;

R^{10} is chosen from (C_1-C_{12}) -alkyl, (C_6-C_{14}) -aryl- (C_1-C_4) -alkyl-, (C_1-C_8) -alkoxy, (C_1-C_4) -alkoxy- (C_2-C_4) -alkoxy-, (C_6-C_{14}) -aryl- (C_1-C_4) -alkoxy-, (C_6-C_{14}) -aryloxy-, Het-oxy-, Het- (C_1-C_4) -alkoxy-, (C_6-C_{14}) -aryl, Het, Het- (C_1-C_4) -alkyl-, trifluoromethoxy, trifluoromethyl, halogen, oxo, hydroxy, amino, (C_1-C_{12}) -alkylcarbonylamino-, aminocarbonylamino-, (C_6-C_{14}) -arylcarbonylamino-, Het-carbonylamino-, (C_6-C_{14}) -aryl- (C_1-C_4) -alkylcarbonylamino-, Het- (C_1-C_4) -alkylcarbonylamino-, (C_1-C_8) -alkylcarbonyl-, (C_6-C_{14}) -arylcarbonyl-, (C_1-C_8) -alkylaminocarbonyl-, (C_6-C_{14}) -arylaminocarbonyl-, (C_6-C_{14}) -aryl- (C_1-C_4) -alkylaminocarbonyl-, Het-aminocarbonyl-, Het- (C_1-C_4) -alkylaminocarbonyl-, aminocarbonyl-, (C_1-C_8) -alkoxycarbonyl-, hydroxycarbonyl-, cyano, nitro, amidino, acetimino, tri- $((C_1-C_4)$ -alkyl)ammonio-, (C_1-C_8) -alkylamino-, di- $((C_1-C_8)$ -alkyl)amino-, hydroxycarbonylmethoxy-, (C_1-C_8) -alkylsulfonyl-, (C_6-C_{14}) -arylsulfonyl-, (C_1-C_8) -alkylaminosulfonyl-, (C_6-C_{14}) -arylaminosulfonyl-, (C_6-C_{14}) -aryl- (C_1-C_4) -alkylaminosulfonyl-, Het-aminosulfonyl-, Het- (C_1-C_4) -

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

A 2

alkylaminosulfonyl-, (C₁-C₈)-alkylsulfonylamino-, (C₆-C₁₄)-
arylsulfonylamino-, (C₆-C₁₄)-aryl-(C₁-C₄)-alkylsulfonylamino-, Het-
sulfonylamino-, and Het-(C₁-C₄)-alkylsulfonylamino-, wherein (C₁-C₁₂)-
alkylcarbonylamino- representing R¹⁰ is unsubstituted or substituted in the
alkyl group by a substituent chosen from amino, hydroxy and (C₁-C₄)-
alkoxy, and wherein (C₁-C₁₂)-alkyl and (C₁-C₈)-alkoxy representing R¹⁰ are
unsubstituted or substituted by at least one identical or different
substituent chosen from (C₁-C₈)-alkoxycarbonyl-, hydroxycarbonyl- and
aminocarbonyl-,

wherein each of the aryl groups and Het group in a group R¹⁰ is
unsubstituted or substituted by at least one identical or different
substituent chosen from halogen, nitro, oxo, hydroxy, (C₁-C₈)-alkyl, (C₁-
C₈)-alkoxy, (C₁-C₄)-alkoxy-(C₂-C₄)-alkoxy-, (C₆-C₁₄)-aryloxy-, (C₆-C₁₄)-aryl-
(C₁-C₄)-alkoxy-, Het-oxy-, Het-(C₁-C₄)-alkoxy-, (C₆-C₁₄)-aryl, (C₆-C₁₄)-aryl-
(C₁-C₄)-alkyl-, Het, Het-(C₁-C₄)-alkyl-, trifluoromethyl, cyano,
trifluoromethoxy, (C₁-C₈)-alkylsulfonyl-, (C₁-C₈)-alkoxycarbonyl-,
hydroxycarbonyl-, aminocarbonyl-, amino, (C₁-C₈)-alkylamino-, di-((C₁-C₈)-
alkyl)amino-, (C₁-C₈)-alkylcarbonylamino-, (C₆-C₁₄)-aryl-(C₁-C₄)-
alkylcarbonylamino-, (C₆-C₁₄)-arylcarbonylamino-, Het-carbonylamino-,
Het-(C₁-C₄)-alkylcarbonylamino-, and (C₁-C₈)-alkylcarbonyl-, wherein (C₁-
C₈)-alkyl and (C₁-C₈)-alkoxy representing a substituent on an aryl group or
Het group in a group R¹⁰ are unsubstituted or substituted by at least one

A2

identical or different substituent chosen from (C₁-C₈)-alkoxycarbonyl-, hydroxycarbonyl- and aminocarbonyl-,

with the proviso that, when a substituent R¹⁰ is bonded to an alkyl group, it cannot be (C₁-C₈)-alkoxycarbonyl-, hydroxycarbonyl-, aminocarbonyl-, (C₁-C₈)-alkylaminocarbonyl-, or (C₁-C₈)-alkylaminosulfonyl-, and that, when a substituent R¹⁰ is bonded to an alkyl group, it cannot be (C₁-C₈)-alkyl which is substituted by at least one identical or different substituent chosen from (C₁-C₈)-alkoxycarbonyl-, hydroxycarbonyl- and aminocarbonyl-;

Het is a residue of a saturated or unsaturated monocyclic or bicyclic, 3-membered to 10-membered heterocyclic ring system containing 1, 2 or 3 identical or different ring heteroatoms chosen from nitrogen, oxygen and sulfur;

or a physiologically tolerable salt thereof, in any stereoisomeric form, or a mixture of any such compounds in any ratio.


A3

7. (AMENDED) A process for the preparation of at least one compound of formula I as claimed in claim 1, comprising linking the compounds of formulae II, III and IV with formation of a (thio)urea bridge between the groups G¹ and G² in formulae II and III and an amide bond between the COZ group in formula II and the NH₂ group in formula IV,


FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com


A3



II



III



IV

wherein

- (a) G^1 is NH_2 and G^2 is chosen from iso(thio)cyanato, (C_1-C_6) -alkoxycarbonylamino, trichloromethylcarbonylamino, and azolyl-N-(thio)carbonylamino, wherein these groups contain the group R^6 ; or
- (b) G^1 is chosen from iso(thio)cyanato, (C_1-C_6) -alkoxycarbonylamino, trichloromethylcarbonylamino, and azolyl-N-(thio)carbonylamino and G^2 is NHR^6 ; and

Z in the compound of formula III is chosen from hydroxy and a nucleophilically substitutable leaving group; R^0 in the compound of formula II is chosen from $R^1NH-C(=NH)-$, a protected form thereof, and a precursor group thereof; and m, n, A, R^1 , R^2 , R^3 , R^4 , R^5 and R^6 are defined as in claim 1, but wherein functional groups can also be present in protected form or in the form of precursor groups.

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

11. (AMENDED) A method of inhibiting or reducing blood clotting or inflammatory response, comprising administering to a patient an effective amount